Recent advances in the treatment of drug resistant tuberculosis
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.38Keywords:
tuberculosis, MDR TB, treatmentAbstract
Multidrug - resistant (MDR TB) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising advances in the paradigm of MDR TB treatment: new drugs have shown activity against Mycobacterium tuberculosis (MBT) and several all - oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.
References
World Health Organization Implementing the End TB Strategy. Antimicrob. Agents Chemother. 2014; 58:7250–7257.
World Health Organization Regional Office for Europe. Roadmap to prevent and combat drug- resistant tuberculosis: the Consol idated Action Plan to Prevent and Combat Multidrug- and Ex tensively Drug-Resistant Tuberculosis in the WHO European Region, 2011–2015 5 p.
European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and mon itoring in Europe 2023–2021 data. Stockholm, Sweden; and Copenhagen, Denmark: ECDC & WHO Regional Office for Europe, 2023, 15 p.
Kohler S, et al. The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer,shorter, and short drug regimens for Karakalpakstan, Uzbekistan. PLoS Glob Public Health 2022;2(8): e0000567.
World Health Organization. WHO Treatment of Tuberculosis Guidelines. 4th ed. World Health Organization; Geneva, Switzerland: 2010, 84 p.
Falzon D., Schünemann H.J., Harausz E., González- Angulo L., Lienhardt C., Jaramillo E., Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur. Respir. J. 2017; 49:1602308.
van Deun A., Maug A.K.J., Salim M.A.H., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182:684–692.
Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., van Deun A. High cure rate with standardised short-course multidrug- resistant tuberculosis treatment in Niger: No relapses. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2014; 18:1188–1194.
Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis. 2015; 19:517–524.
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment— Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 12 p.
Rapid сcommunication: key changes to treatment of multidrug and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/275383).
WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022, 6 p. (https://iris.who.int/handle/10665/365308).
Key updates to the treatment of drug-resistant tuberculosis: rapid communication, August 2024, 3 p. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378472).
WHO Consolidated guidelines on drug-resistant tuberculosis treatment, WHO, 2019, 19 p. https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
World Health Organization. Who Consolidated Guidelines on Tuberculosis. Module 4: Treatment — Drug-Resistant Tuberculosis Treatment. World Health Organization; Geneva, Switzerland: 2020, 41 p.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
